Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453250 | 1.00 | BRD4 (0.46) | BRD4CHEK1CYP3A4CYP3A5PIK3CA | |
| SCHEMBL11904207 | 0.90 | BRD4 (0.41) | BRD4CHEK1CYP3A4CYP3A5PIK3CA | |
| SCHEMBL1029868 | 0.74 | SMN1; SMN2 (0.51) | BRD4CHEK1PIK3CAMTORPIK3CG | |
| SCHEMBL2495047 | 0.74 | CDK5 (0.45) | CHEK1CYP3A4GAAGFERKDM4E | |
| SCHEMBL2027413 | 0.73 | CYP3A4 (0.68) | BRD4CYP3A4CYP3A5 | |
| SCHEMBL28083058 | 0.71 | TOP2A (0.49) | CYP3A4SMN1; SMN2GAAGFERKDM4E | |
| SCHEMBL7428184 | 0.70 | TDO2 (0.40) | GAAGFERKDM4EALDH1A1 | |
| SCHEMBL5998120 | 0.69 | PIK3CA (0.46) | CHEK1PIK3CAMTORPIK3CGSMN1; SMN2 | |
| SCHEMBL10379222 | 0.68 | PIK3CA (0.57) | CHEK1PIK3CAMTORPIK3CGSMN1; SMN2 | |
| SCHEMBL540122 | 0.68 | MGMT (0.58) | CYP3A4PIK3CAMTORPIK3CGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281603-A1 | Compositions for the Treatment of Infectious Disease Related Complications and Methods Thereof | AMARANTUS BIOSCIENCE HOLDINGS (US) | 2025-09-11 | — | — | US | claimed |
| WO-2025105897-A1 | METHOD FOR DETECTING GENOMIC MUTATION THROUGH NUCLEIC ACID PATTERN-BASED PURIFICATION, AND DISEASE DIAGNOSIS METHOD USING SAME | 광주과학기술원 | 2025-05-22 | — | — | WO | claimed |
| US-20250154557-A1 | COMPOSITION FOR SELECTING NUCLEIC ACIDS OF INTEREST, AND A METHOD FOR SELECTING NUCLEIC ACIDS USING THEREOF | GWANGJU INST SCIENCE & TECH (KR) | 2025-05-15 | — | — | US | claimed |
| WO-2024148136-A1 | ENZYMATIC DNA SYNTHESIS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2024-07-11 | — | — | WO | claimed |
| WO-2023212658-A2 | COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS DISEASE RELATED COMPLICATIONS AND METHODS THEREOF | AMARANTUS BIOSCIENCE HOLDINGS (US) | 2023-11-02 | — | — | WO | claimed |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-20220315926-A1 | An Aptamer for Dengue Virus and Related Methods and Products | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-10-06 | — | — | US | claimed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| EP-3987035-A1 | AN APTAMER FOR DENGUE VIRUS AND RELATED METHODS AND PRODUCTS | Agency for Science, Technology and Research (SG) | 2022-04-27 | — | — | EP | claimed |
| US-20210292757-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-09-23 | — | — | US | claimed |
| US-20150152496-A1 | METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER | KABUSHIKI KAISHA DNAFORM (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2873731-A1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | Kabushiki Kaisha Dnaform (JP) | 2015-05-20 | — | — | EP | claimed |
| US-20150038554-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20150038555-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20130041010-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | claimed |
| US-8067162-B2 | Replication; hybridization; kits | RIKEN (JP) | 2011-11-29 | — | — | US | claimed |
| US-20110288147-A1 | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop | DICERNA PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | claimed |
| EP-2341943-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | Dicerna Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| US-20100331389-A1 | Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides | DICERNA PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2010033225-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | BRD4 4427/4885CHEK1 3052/4885CYP3A4 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.